Previous 10 | Next 10 |
home / stock / envb / envb articles
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury Results of a first-in-class clinical trial on ibogaine-magnesium th...
Shares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a December 2023 business update. The compa...
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Au...
John Lennon Remembered 43 Years After His Murder In New York, Psychedelic Adventures & Enduring Legacy The world seemed to come to a momentary ...
Defense Dept. Funds Ketamine Study For PTSD Treatment A DOD Health Agency-funded adaptive platform trial for alternative treatments for ...
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan Vivek Ramaswamy, who famously said he did no...
Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety,...
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans? An average of 17 veterans committed suicide per day in 2020...
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court The U.S. Court of Appeals for the Ninth Circuit ruled against the Drug Enforc...
News, Short Squeeze, Breakout and More Instantly...
Enveric Biosciences Inc Com Company Name:
ENVB Stock Symbol:
NASDAQ Market:
Enveric Biosciences Inc Com Website:
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
EB-003 is a novel, neuroplastogenic molecule designed to treat severe mental health disorders without the hallucinogenic effect typically associated with psychedelic-based compounds Enveric is advancing pre-clinical development of EB-003 with a pre-IND meeting targeted for early 2025 ...
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Com...